Abstract: The present invention concerns a medical device detectable by magnetic resonance imaging (MRI), said medical device comprising an envelope polymer that is at least partly removed at the distal end of the medical device wherein said distal end is provided with a coating comprising a coating polymer modified with at least one chemical compound having one or more chemically active free functional groups to provide a surface coating covalently bonded to the free functional groups of the modified coating polymer, wherein paramagnetic ions are encompassed in the coating.
Abstract: The invention provides a drug conjugate comprising: 1) a therapeutic agent that comprises a phosphate, phosphonate, carboxy, or phosphoramidate group, and 2) a fluorescent group linked to the phosphate, phosphonate, carboxy, or phosphoramidate group to form the corresponding ester and salts thereof. The conjugates are useful for therapy and as probes. The invention also provides therapeutic methods for treating diseases with conjugates of the invention as well as methods for determining optimal dosages of a conjugate or a therapeutic agent for a given patient using a conjugate of the invention.
Type:
Grant
Filed:
July 14, 2016
Date of Patent:
October 27, 2020
Assignees:
University of Iowa Research Foundation, University of Connecticut
Inventors:
David F. Wiemer, Rocky J. Barney, Andrew Wiemer
Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance:additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
Abstract: A composition for neutron capture therapy and a method of preparing the same are provided. The composition includes at least one nanodiamond particle and at least one neutron capture element, in which the at least one neutron capture element is embedded into the at least one nanodiamond particle by using an ion implantation system.
Type:
Grant
Filed:
May 11, 2016
Date of Patent:
October 13, 2020
Inventors:
Huan Niu, Chien Hsu Chen, Causon Ko-Chuan Jen
Abstract: A group of Hyperthermia micro/nano particles are prepared. Each nanoparticle has a first diameter between 1 micron to 50 micron and a first thickness between 100 nm to 5 micron, in a disk-like shape. The hyperthermia micro/nano particles in the present show enhanced heat properties under microwave radiation which can be used for diagnosis and therapeutic purpose in cancer treatment.
Type:
Grant
Filed:
July 31, 2016
Date of Patent:
September 29, 2020
Inventors:
Wei Wu, Yifei Wang, Mahta Moghaddam, John Stang
Abstract: A method for allowing an animal to develop atrioventricular block, the method including: administering an immune regulator targeting a sphingosine-1-phosphate receptor to an animal selected from a pig, a monkey and a guinea pig.
Abstract: The present invention discloses fluorescent compounds and a method for their use for selective imaging of blood vessels and blood flow. By applying these fluorescent compounds and the imaging process to a zebrafish model, the present invention further provides methods and procedures for the discovery, selection, and characterization of pro- and anti-angiogenic agents.
Abstract: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.
Type:
Grant
Filed:
September 2, 2016
Date of Patent:
August 4, 2020
Assignee:
GRÜNENTHAL GMBH
Inventors:
Elisabeth Arkenau-Marić, Johannes Bartholomäus
Abstract: There is disclosed a composition in the form of a nanoparticle. The nanoparticle composition has a diameter from 5 to 500 nanometers. The nanoparticle composition has i) a central core portion including magnetic Fe3O4 nanoparticles adapted to act as a heat source when subjected to a magnetic field and a chemotherapeutic agent configured to treat cancer tissues, ii)—a shell portion including a shell member encapsulating said core portion, and iii)—antibodies configured to target cancer stem cells and adhered to surface of said shell member. The chemotherapeutic agent is a heat shock protein inhibitor and is releasable on activation of the heat source due to the magnetic field, and the shell member is made of silica or a silica based material.
Abstract: The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.
Abstract: A method directed to a hair soaking treatment for frizz reduction comprising immersion of consumer hair into an aqueous composition is disclosed. A method for hair frizz reduction wherein hair is soaked for at least about 2 minutes in an aqueous composition having a viscosity of less than about 1000 cP comprising from about 0.
Type:
Grant
Filed:
April 2, 2015
Date of Patent:
May 26, 2020
Assignee:
The Procter and Gamble Company
Inventors:
Supriya Punyani, Jennifer Mary Marsh, James Charles Dunbar, Curtis Bobby Motley, Lisa Jo Bartz, Erica Vencil Buckner
Abstract: Provided herein are theranostic compositions comprising a Janus nanoparticle-coated microbubble that are useful for imaging (e.g., MRI, or ultrasound) and for delivering a therapeutic or bioactive agent (e.g., nucleic acid(s), drugs, etc), among other uses.
Type:
Grant
Filed:
February 18, 2016
Date of Patent:
February 25, 2020
Assignee:
TRUSTEES OF BOSTON UNIVERSITY
Inventors:
Joyce Y. Wong, Ragnhild D. Whitaker, Nelson Ruiz-Opazo, Victoria L. M. Herrera
Abstract: The present invention concerns heterometallic metallacrown compounds incorporating Ga(III) and Ln(III) cations, with a templating ligand such as salicylhydroxamic acid or derivatives thereof, wherein said metallacrown contains at least one repeating [—Ga—N—O—] sub-unit where the N—O derives from the templating ligand.
Type:
Grant
Filed:
April 18, 2016
Date of Patent:
February 18, 2020
Assignees:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Evan R. Trivedi, Vincent L. Pecoraro, Svetlana V. Eliseeva, Stépane Petoud, Chun Y. Chow, Tu Ngoc Nguyen, Jacob Charles Lutter, Ivana Martinic
Abstract: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.
Type:
Grant
Filed:
May 16, 2016
Date of Patent:
January 7, 2020
Assignee:
Georgia State University Research Foundation, Inc.
Abstract: Disclosed herein is an injectable anticancer composition for local administration, which contains a suspension of quinine hydrochloride. The anticancer composition for local administration according to the present invention shows an IC50 value against MKN-45 cells, which is about 10 times lower than Paclitaxel, as determined by an MTT assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect. The anticancer composition can be administered as a safe anticancer agent in clinical applications, and also shows an anticancer effect by inducing the necrosis and detachment of solid cancer cells. Particularly, the anticancer composition has an anticancer mechanism by which the composition acts locally in a tumor tissue administered with the composition and shows a rapid antitumor effect (1-2 weeks after administration).
Abstract: The present invention relates to a composition for use as a contrast agent in medical imaging. The composition comprises a metal ion containing compound comprises at least one metal ion adapted to bind with one or more metal ion chelating agents; wherein said one or more metal ion chelating agents comprise at least one first chelating agent adapted to target a region of interest being imaged, and at least one second chelating agent having at least one functional group adapted to dissociate in an aqueous medium to thereby allow or enhance contrast of the region of interest under the medical imaging. The present invention further relates to a diagnostic agent for use in amyloid (A?) protein detection under magnetic resonance imaging (MRI) comprising the above described composition; and a method of preparing thereof.
Abstract: Provided is a topical formulation comprising (1) three or more of the following four components a through d, or (2) component c and one or more of components a, b or d: (a) a skin barrier repair formulation comprising fatty acid, bilayer-stabilizing steroid, and complex lipid (CL), wherein the weight ratio of CL to steroid is from about 1.5:1 to about 8:1, and the weight ration of CL to FA is from about 4:1 to about 1:1, the lipids present in an amount from about 3% wt. to about 10% wt.; (b) a natural moisturizer formulation, wherein the natural moisturizers are urea, urocanic acid, pyrrolidone-5-carboxylic acid, lactic acid or free amino acid; (c) one or more retinoids in an amount from about 0.01% wt. to about 10% wt.; or (d) taurine in an amount from about 0.1% wt. to about 5% wt.
Type:
Grant
Filed:
December 22, 2015
Date of Patent:
September 10, 2019
Assignee:
TetraDerm Group LLC
Inventors:
Thomas Sköld, Georgia Levis, Michael J. Burns
Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.
Type:
Grant
Filed:
April 6, 2012
Date of Patent:
August 20, 2019
Assignee:
CEDARS-SINAI MEDICAL CENTER
Inventors:
Keith L. Black, Julia Ljubimova, Alexander Ljubimov, Eggehard Holler
Abstract: Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganese-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent.
Type:
Grant
Filed:
January 26, 2017
Date of Patent:
July 9, 2019
Assignee:
Georgetown University
Inventors:
Sarah Stoll, Julie Quinn, Edward Van Keuren, Christopher Albanese, Stanley Fricke
Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
Type:
Grant
Filed:
March 20, 2017
Date of Patent:
March 19, 2019
Assignee:
Baxter International Inc.
Inventors:
Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser